K. A. Dicke

2.0k total citations · 1 hit paper
16 papers, 1.6k citations indexed

About

K. A. Dicke is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, K. A. Dicke has authored 16 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 6 papers in Oncology and 5 papers in Genetics. Recurrent topics in K. A. Dicke's work include Acute Myeloid Leukemia Research (6 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). K. A. Dicke is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). K. A. Dicke collaborates with scholars based in United States, United Kingdom and France. K. A. Dicke's co-authors include Sundar Jagannath, Jamés O. Armitage, Barthel Barlogie, A Zander, Gary Spitzer, Raymond Alexanian, Norbert Claude Gorin, Thierry Philip, Franck Chauvin and A H Goldstone and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

K. A. Dicke

16 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High-Dose Therapy and Autologous Bone Marrow Transplantation after Failure of Conventional Chemotherapy in Adults with Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

1987 642 citations Thierry Philip, Jamés O. Armitage et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by K. A. Dicke

Since Specialization

Citations

This map shows the geographic impact of K. A. Dicke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. A. Dicke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. A. Dicke more than expected).

Fields of papers citing papers by K. A. Dicke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. A. Dicke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. A. Dicke. The network helps show where K. A. Dicke may publish in the future.

Co-authorship network of co-authors of K. A. Dicke

This figure shows the co-authorship network connecting the top 25 collaborators of K. A. Dicke. A scholar is included among the top collaborators of K. A. Dicke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. A. Dicke. K. A. Dicke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Hematologic side effects of radiolabeled immunoglobulin therapy. 1996 ·PubMed ·H. M. Vriesendorp, Syed M. Quadri, B Andersson, K. A. Dicke	38
2	HLA-identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukemia in first remission. 1996 ·PubMed ·Robert Peter Gale, Thomas Büchner, M-J Zhang, Achim Heinecke, Richard Champlin, K. A. Dicke, Éliane Gluckman, R. A. Good, Aloïs Gratwohl, RH Herzig, Armand Keating, John P. Klein, A Marmont, H. G. Prentice, Philip A. Rowlings, K. A. Sobocinski, B Speck, Roy S. Weiner, Mary M. Horowitz	32
3	High dose therapy for acute myelocytic leukemia treatment strategy: What is the choice? 1993 ·Annals of Oncology ·Norbert Claude Gorin, K. A. Dicke, Bob Löwenberg	11
4	High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long term follow-up in 128 patients 1993 ·Annals of Oncology ·Philip J. Bierman, Robert Bagin, Sundar Jagannath, Julie M. Vose, Gary Spitzer, Anne Kessinger, K. A. Dicke, Jamés O. Armitage	122
5	Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease. 1993 ·Journal of Clinical Oncology ·P. J. Bierman, J. M. Vose, Peter K. Leichner, Syed M. Quadri, J. O. Armitage, J Klein, (unknown), K. A. Dicke, H. M. Vriesendorp	37
6	Autotransplants: now and in the future. 1991 ·PubMed ·R P Gale, J. O. Armitage, K. A. Dicke	15
7	Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. 1990 ·Journal of Clinical Oncology ·Hagop M. Kantarjian, R S Walters, Michael J. Keating, Terry L. Smith, Stephen O’Brien, Elihu H. Estey, Yang O. Huh, Jorge A. Spinolo, K. A. Dicke, Barthel Barlogie	136
8	Double intensification with amsacrine/high dose ara-C and high dose chemotherapy with autologous bone marrow transplantation produces durable remissions in acute myelogenous leukemia. 1990 ·PubMed ·(unknown), K. A. Dicke, (unknown), S Jagannath, A Zander, (unknown), G Spitzer	5
9	Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. 1989 ·Journal of Clinical Oncology ·Sundar Jagannath, Jamés O. Armitage, K. A. Dicke, S.L. Tucker, William S. Velasquez, Kerrington D. Smith, William P. Vaughan, Anne Kessinger, Leonard Horwitz, Fredrick B. Hagemeister	172
10	Piperazinedione plus total body irradiation: an alternative preparative regimen for allogeneic bone marrow transplantation in advanced phases of chronic myelogenous leukemia. 1989 ·PubMed ·Leonard Horwitz, Hagop M. Kantarjian, (unknown), Michael J. Keating, K. B. McCredie, Gary Spitzer, L Vellekoop, A Zander, K. A. Dicke	4
11	A comparison of marrow transplantation with chemotherapy for adults with acute leukemia of poor prognosis in first complete remission. 1988 ·Journal of Clinical Oncology ·A Zander, Michael J. Keating, K. A. Dicke, Dennis O. Dixon, Sherry Pierce, Sundar Jagannath, L. J. Peters, Leonard Horwitz, (unknown), Gary Spitzer	41
12	High-Dose Therapy and Autologous Bone Marrow Transplantation after Failure of Conventional Chemotherapy in Adults with Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma breakdown → 1987 ·New England Journal of Medicine ·Thierry Philip, Jamés O. Armitage, Gary Spitzer, Franck Chauvin, Sundar Jagannath, Jean‐Yves Cahn, Philippe Colombat, A H Goldstone, Norbert Claude Gorin, (unknown), Jean-Philippe Laporte, D Maraninchi, (unknown), André Bosly, Cathy M. Anderson, Rik Schots, Pierre Biron, Fernando Cabanillas, K. A. Dicke	642
13	High-dose melphalan with autologous bone marrow transplantation for multiple myeloma 1986 ·Blood ·Barthel Barlogie, (unknown), A Zander, K. A. Dicke, Raymond Alexanian	260
14	Human Adherent Cell Contact-Mediated Modulation of Normal Myeloid Colony Formation<xref ref-type="fn" rid="FN2">2</xref><xref ref-type="fn" rid="FN3">3</xref> 1982 ·JNCI Journal of the National Cancer Institute ·(unknown), (unknown), (unknown), A Zander, (unknown), K. A. Dicke	5
15	Effect of Oxymetholone on Human Cyclic Haematopoiesis 1981 ·British Journal of Haematology ·K. J. Roozendaal, K. A. Dicke, (unknown)	13
16	High-dose BCNU therapy with autologous bone marrow infusion: preliminary observations. 1979 ·PubMed ·Gary Spitzer, K. A. Dicke, D. S. Verma, A Zander, K. B. McCredie	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact